Welcome to our dedicated page for Summit Therapeutics SEC filings (Ticker: SMMT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Summit Therapeutics Inc.'s SEC filings document the company's oncology development business, regulatory updates, governance, and capital structure. Form 8-K reports cover financial results, Regulation FD presentations, ivonescimab clinical data, FDA acceptance of the Biologics License Application, and clinical collaboration disclosures involving investigational cancer combinations.
Definitive proxy materials describe board matters, executive compensation, equity awards, shareholder voting items, and governance practices. The filing record also includes material-event disclosures, material agreements, operating and financial results, and capital-structure information for Summit's Nasdaq-listed common stock and its development rights to ivonescimab.
Summit Therapeutics Inc. reported results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected nine directors to serve until the 2027 annual meeting and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. They also approved an amendment to the Summit Therapeutics Inc. 2020 Stock Incentive Plan to increase the number of shares of common stock issuable under the plan by 8,000,000 shares, providing additional equity for future grants.
Summit Therapeutics Inc. Co-CEO Mahkam Zanganeh reported a large indirect open-market purchase of 3,810,000 shares of Common Stock at $13.12 per share on behalf of her spouse. The filing also lists existing holdings, including 31,000 direct shares and substantial indirect stakes through family trusts and an immediate family member. A footnote states she disclaims beneficial ownership beyond her pecuniary interest.
Summit Therapeutics Inc. Co-Chief Executive Officer and director Robert W. Duggan reported an open-market purchase of 3,810,000 shares of common stock at $13.12 per share. After this transaction, he directly holds 573,883,879 shares of Summit Therapeutics common stock.
The filing also lists indirect holdings attributed to entities and individuals related to him, including 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust, 25,824,474 shares held by the Mahkam Zanganeh Revocable Trust, 31,000 shares held by his spouse, and 76,680 shares held by an immediate family member of his spouse. He disclaims beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.
Summit Therapeutics Inc. has withdrawn its previously announced proposed underwritten public offering of securities, effective June 10, 2026, citing market conditions. Because the offering has been terminated, no securities will be sold under that proposed transaction. The update is provided as a Regulation FD disclosure and is not treated as a filed report for liability purposes under Section 18 of the Exchange Act.
Summit Therapeutics Inc. intends to offer $500.0 million of common stock in a registered primary offering, with an at‑the‑market program complement and a 30‑day underwriter option for up to $75,000,000 of additional shares.
The preliminary prospectus supplement states an assumed public offering price of $14.11 per share, implying 35,435,861 shares offered at that price. The company reported 776,017,474 shares outstanding as of March 31, 2026, net tangible book value of $544.0 million (or $0.70 per share), and approximately 118.9 million shares subject to outstanding options or RSUs as of that date. Summit says net proceeds will fund continued development of ivonescimab and for working capital, and notes substantial doubt about its ability to continue as a going concern absent additional funding.
Summit Therapeutics Inc. filed a shelf registration on Form S-3 to permit offers and sales of common stock, preferred stock, debt securities, depositary shares, warrants, subscription rights and units from time to time after the effective date.
The prospectus states the company’s common stock last traded at $14.11 per share on June 8, 2026, and discloses a going concern warning: management concluded there is substantial doubt about the company’s ability to continue as a going concern absent additional funding for the next twelve months. The prospectus reserves no specific aggregate offering amount and says net proceeds will be used for general corporate purposes, with specific terms to be provided in prospectus supplements.
Summit Therapeutics Inc. director and Co‑CEO Robert W. Duggan reported an indirect open‑market purchase of 100,000 shares of Common Stock at $14.60 per share. The transaction was made by the Mahkam Zanganeh Revocable Trust, with his spouse as trustee, bringing that trust’s reported holdings to 25,824,474 shares.
The filing also lists additional positions associated with Duggan, including 570,073,879 shares held directly, 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust, 31,000 shares held by his spouse, and 76,680 shares held by an immediate family member of his spouse. A footnote states he disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Summit Therapeutics Inc. Co-Chief Executive Officer Mahkam Zanganeh, acting through the Mahkam Zanganeh Revocable Trust where she serves as trustee, bought 100,000 shares of common stock in an open-market purchase at $14.60 per share.
Following this transaction, that revocable trust held 25,824,474 shares of Summit Therapeutics common stock. Additional holdings reported include 31,000 shares held directly, 10,199,776 shares held by the Shaun Zanganeh Irrevocable Trust with her as trustee, 570,073,879 shares held by her spouse, and 76,680 shares held by an immediate family member. She disclaims beneficial ownership of these securities beyond any pecuniary interest.
Summit Therapeutics Inc. director and executive officer Manmeet Singh Soni, who serves as COO and CFO, reported open-market purchases of the company’s common stock. On June 4, 2026, he bought 25,000 shares at $14.43 and another 25,000 shares at $14.46.
These transactions total 50,000 shares of Summit Therapeutics common stock acquired in the open market, leaving him with a direct ownership stake of more than three million shares.
Summit Therapeutics Inc. stated that on June 2, 2026, its Audit Committee and all independent directors approved one or more Company affiliates to purchase shares of its common stock through the Company’s previously disclosed at-the-market offering with JP Morgan Securities LLC as Sales Agent.
The Company also noted that Co-CEO and Chairman Robert Duggan, Co-CEO and President Dr. Mahkam Zanganeh, and COO/CFO Manmeet Soni have indicated they are likely to purchase shares under this at-the-market program in the near term. These executives have not specified how many shares they may buy and have made no binding commitments. Any purchases would occur at the prevailing market bid price or better.